There were no significant differences between the patients with GalNAc-T3 negative and positive tumour expressions regarding age, gender, tumour location, size, lymph node involvement, disease stage, margin status, lymphatic invasion, VI, perineural invasion or serum CA19-9 or CEA level (P>0.05), whereas GalNAc-T3 staining status significantly affected tumour differentiation (P=0.001; Figures 2C, E, and G). This evidence concerns the gene CEACAM5 and neoplasm.